You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClorazepate
Accession NumberDB00628  (APRD00881)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions. [PubChem]
Structure
Thumb
Synonyms
7-chloro-2,3-dihydro-2,2-Dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid
Clorazepate
Clorazepic acid
External Identifiers
  • Abbott 35616
  • AH 3232
  • CB 4306
  • Ro 6-6616
  • TR 19119
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ClorazepateCapsule3.75 mgOralAa Pharma Inc1990-12-31Not applicableCanada
ClorazepateCapsule7.5 mgOralAa Pharma Inc1990-12-31Not applicableCanada
ClorazepateCapsule15 mgOralAa Pharma Inc1990-12-31Not applicableCanada
Novo-clopate Cap 15mgCapsule15 mgOralNovopharm Limited1984-12-312015-10-26Canada
Novo-clopate Cap 3.75mgCapsule3.75 mgOralNovopharm Limited1984-12-312015-10-26Canada
Novo-clopate Cap 7.5mgCapsule7.5 mgOralNovopharm Limited1984-12-312015-10-26Canada
Tranxene Cap 15mgCapsule15 mgOralAbbott Laboratories, Limited1973-12-312003-08-01Canada
Tranxene Cap 3.75mgCapsule3.75 mgOralAbbott Laboratories, Limited1973-12-312003-08-01Canada
Tranxene Cap 7.5mgCapsule7.5 mgOralAbbott Laboratories, Limited1976-12-312003-08-01Canada
Tranxene T-tabTablet3.75 mg/1OralRECORDATI RARE DISEASES, INC.1972-06-232016-10-13Us
Tranxene T-tabTablet7.5 mg/1OralRECORDATI RARE DISEASES, INC.1972-06-23Not applicableUs
Tranxene T-tabTablet15 mg/1OralRECORDATI RARE DISEASES, INC.1972-06-232016-10-13Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clorazepate DipotassiumTablet7.5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-29Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralREMEDYREPACK INC.2016-07-15Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1OralMylan Pharmaceuticals Inc.1987-07-17Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralRanbaxy Pharmaceuticals Inc.2005-01-14Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-04-27Not applicableUs
Clorazepate DipotassiumTablet15 mg/1Oralbryant ranch prepack2000-04-27Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralRebel Distributors Corp2000-04-27Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralPd Rx Pharmaceuticals, Inc.2005-01-14Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralREMEDYREPACK INC.2016-07-15Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralMylan Pharmaceuticals Inc.1987-07-17Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralRanbaxy Pharmaceuticals Inc.2005-01-14Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-04-27Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralContract Pharmacy Services Pa2011-03-29Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-29Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1OralREMEDYREPACK INC.2010-11-182016-10-13Us
Clorazepate DipotassiumTablet3.75 mg/1OralREMEDYREPACK INC.2016-07-21Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralMylan Pharmaceuticals Inc.1987-07-17Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1Oralbryant ranch prepack2000-04-27Not applicableUs
Clorazepate DipotassiumTablet15 mg/1OralA S Medication Solutions Llc2000-04-27Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1OralAmerican Health Packaging2014-07-312017-05-31Us
Clorazepate DipotassiumTablet7.5 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-29Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-04-27Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1OralRebel Distributors Corp2000-04-27Not applicableUs
Clorazepate DipotassiumTablet7.5 mg/1Oralbryant ranch prepack2005-01-14Not applicableUs
Clorazepate DipotassiumTablet3.75 mg/1OralRanbaxy Pharmaceuticals Inc.2005-01-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnksenSanovel
CalnerMedipharm
CloranxenTeva
Clorazepatumsanofi-aventis
ClozeneWeidar
DipotAsian
FluliumPharmasant
Gen-xeneAlra
JustumSandoz
ManotranMarch
MedipaxTecnifar
MendonAbbott Japan
PolizepPolipharm
TencilanFinadiet
TrancapT P Drug
Transenesanofi-aventis
Tranxensanofi-aventis
Tranxènesanofi-aventis
TranxeneLundbeck
Tranxilenesanofi-aventis
Tranxiliumsanofi-aventis
Zetran-5Masa Lab
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clorazepate dipotassium
ThumbNot applicableDBSALT000953
Categories
UNIID51WO0G0L4
CAS number23887-31-2
WeightAverage: 314.723
Monoisotopic: 314.045819935
Chemical FormulaC16H11ClN2O3
InChI KeyXDDJGVMJFWAHJX-UHFFFAOYSA-N
InChI
InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
IUPAC Name
7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
SMILES
OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2
Pharmacology
IndicationFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
Structured Indications
PharmacodynamicsClorazepate is a member of the group of drugs called benzodiazepines. Pharmacologically, clorazepate has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. Studies in healthy men have shown that clorazenate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
TargetKindPharmacological actionActionsOrganismUniProt ID
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Translocator proteinProteinunknown
agonist
HumanP30536 details
Related Articles
AbsorptionRapidly absorbed following oral administration (bioavailability is 91%).
Volume of distributionNot Available
Protein bindingThe protein binding of nordiazepam in plasma is high (97-98%).
Metabolism

The drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.

SubstrateEnzymesProduct
Clorazepate
Not Available
OxazepamDetails
Clorazepate
Not Available
3-hydroxynordiazepamDetails
Clorazepate
NordiazepamDetails
Clorazepate
Not Available
p-HydroxynordiazepamDetails
Route of eliminationThe drug is metabolized in the liver and excreted primarily in the urine.
Half lifeThe serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
ClearanceNot Available
ToxicityOral LD50 in rats is 1320 mg/kg. In monkeys, oral LD50 exceed 1600 mg/kg. Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Clorazepate is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Clorazepate is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clorazepate.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Clorazepate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amperozide.Experimental
AprepitantThe serum concentration of Clorazepate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Asenapine.Approved
AtazanavirThe metabolism of Clorazepate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Clorazepate can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Azaperone.Vet Approved
AzelastineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Clorazepate can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Clorazepate can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Clorazepate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Clorazepate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clorazepate.Approved, Investigational
BuprenorphineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clorazepate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clorazepate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clorazepate.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Clorazepate can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Clorazepate can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clorazepate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clorazepate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clorazepate.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Clorazepate is combined with Citalopram.Approved
ClarithromycinThe metabolism of Clorazepate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Clorazepate can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonidine.Approved
ClotrimazoleThe metabolism of Clorazepate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clozapine.Approved
CobicistatThe metabolism of Clorazepate can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clorazepate.Approved, Illicit
ConivaptanThe serum concentration of Clorazepate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Clorazepate can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Clorazepate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Clorazepate can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clorazepate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Clorazepate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Clorazepate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Clorazepate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clorazepate can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Clorazepate is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Clorazepate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Clorazepate can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Clorazepate can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doxepin.Approved
DoxycyclineThe metabolism of Clorazepate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Clorazepate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
DronedaroneThe metabolism of Clorazepate can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Clorazepate is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Clorazepate can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clorazepate.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Clorazepate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Clorazepate can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Clorazepate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clorazepate.Approved
EthanolClorazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clorazepate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clorazepate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Clorazepate can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flibanserin.Approved
FluconazoleThe metabolism of Clorazepate can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clorazepate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Clorazepate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Clorazepate can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clorazepate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Clorazepate.Approved
FospropofolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Clorazepate can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Clorazepate is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneClorazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clorazepate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
IdelalisibThe serum concentration of Clorazepate can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Iloperidone.Approved
ImatinibThe metabolism of Clorazepate can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Clorazepate can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Clorazepate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Isoflurane.Approved, Vet Approved
IsradipineThe metabolism of Clorazepate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Clorazepate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Clorazepate can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Clorazepate can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clorazepate.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lofentanil.Illicit
LopinavirThe metabolism of Clorazepate can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clorazepate.Approved
LovastatinThe metabolism of Clorazepate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clorazepate.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Clorazepate is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Clorazepate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Clorazepate can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Clorazepate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Metaxalone.Approved
MethadoneClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clorazepate.Approved
MethotrimeprazineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methylphenobarbital.Approved
MetyrosineClorazepate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Clorazepate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Clorazepate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Investigational
MirtazapineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Clorazepate can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Clorazepate can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clorazepate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Investigational
NafcillinThe serum concentration of Clorazepate can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Clorazepate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Clorazepate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Clorazepate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Clorazepate can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Clorazepate can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clorazepate.Approved, Investigational
OlaparibThe metabolism of Clorazepate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Clorazepate is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Clorazepate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineClorazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Clorazepate is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Clorazepate can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clorazepate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Clorazepate can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paliperidone.Approved
ParaldehydeClorazepate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Clorazepate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
PerazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clorazepate.Approved
PhenobarbitalThe metabolism of Clorazepate can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clorazepate.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Clorazepate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleClorazepate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clorazepate.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prilocaine.Approved
PrimidoneThe metabolism of Clorazepate can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clorazepate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Clorazepate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Clorazepate can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clorazepate.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clorazepate.Approved
RifabutinThe metabolism of Clorazepate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Clorazepate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Clorazepate can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Clorazepate can be increased when it is combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Romifidine.Vet Approved
RopiniroleClorazepate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clorazepate.Approved
RotigotineClorazepate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clorazepate.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Clorazepate is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Clorazepate is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Clorazepate can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clorazepate.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Clorazepate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Clorazepate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Clorazepate can be increased when it is combined with Simeprevir.Approved
Sodium oxybateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
St. John's WortThe serum concentration of Clorazepate can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Clorazepate can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Clorazepate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clorazepate.Approved
SuvorexantClorazepate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Clorazepate can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Clorazepate can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Clorazepate can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clorazepate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrodotoxin.Investigational
ThalidomideClorazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clorazepate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiapride.Investigational
TiclopidineThe metabolism of Clorazepate can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Clorazepate can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clorazepate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clorazepate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Clorazepate is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clorazepate.Approved, Investigational
VenlafaxineThe metabolism of Clorazepate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Clorazepate can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Clorazepate can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Clorazepate can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Clorazepate can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zolazepam.Vet Approved
ZolpidemClorazepate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis Reference

Schmitt, J.; U.S. Patent 3,516,988; June 23, 1970.

General References
  1. Authors unspecified: Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. Br Med J. 1980 Mar 29;280(6218):910-2. [PubMed:7388368 ]
  2. McElhatton PR: The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994 Nov-Dec;8(6):461-75. [PubMed:7881198 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9285
Blood Brain Barrier+0.8373
Caco-2 permeable+0.5909
P-glycoprotein substrateNon-substrate0.5597
P-glycoprotein inhibitor INon-inhibitor0.9328
P-glycoprotein inhibitor IINon-inhibitor0.9386
Renal organic cation transporterNon-inhibitor0.9049
CYP450 2C9 substrateNon-substrate0.7365
CYP450 2D6 substrateNon-substrate0.8745
CYP450 3A4 substrateNon-substrate0.5798
CYP450 1A2 substrateInhibitor0.7086
CYP450 2C9 inhibitorNon-inhibitor0.756
CYP450 2D6 inhibitorNon-inhibitor0.819
CYP450 2C19 inhibitorNon-inhibitor0.7451
CYP450 3A4 inhibitorNon-inhibitor0.8333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8165
Ames testNon AMES toxic0.8311
CarcinogenicityNon-carcinogens0.659
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9282 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9987
hERG inhibition (predictor II)Non-inhibitor0.9207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Able laboratories inc
  • American therapeutics inc
  • Clonmel healthcare ltd
  • Gd searle llc
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Sandoz inc
  • Usl pharma inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Lundbeck inc
  • Lederle laboratories div american cyanamid co
  • Ranbaxy laboratories ltd
  • Taro pharmaceuticals usa inc
  • Alra laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral15 mg
CapsuleOral3.75 mg
CapsuleOral7.5 mg
TabletOral15 mg/1
TabletOral3.75 mg/1
TabletOral7.5 mg/1
Prices
Unit descriptionCostUnit
Tranxene t-tablet 15 mg5.41USD tablet
Tranxene-T 15 mg tablet5.08USD tablet
Tranxene t-tablet 7.5 mg3.99USD tablet
Tranxene-T 7.5 mg tablet3.6USD tablet
Tranxene t-tablet 3.75 mg3.21USD tablet
Tranxene-T 3.75 mg tablet3.04USD tablet
Clorazepate 15 mg tablet2.17USD tablet
Clorazepate Dipotassium 15 mg tablet1.27USD tablet
Clorazepate Dipotassium 7.5 mg tablet0.93USD tablet
Clorazepate 7.5 mg tablet0.79USD tablet
Clorazepate Dipotassium 3.75 mg tablet0.76USD tablet
Clorazepate 3.75 mg tablet0.73USD tablet
Apo-Clorazepate 15 mg Capsule0.4USD capsule
Apo-Clorazepate 7.5 mg Capsule0.2USD capsule
Apo-Clorazepate 3.75 mg Capsule0.15USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery solubleNot Available
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0248 mg/mLALOGPS
logP2.68ALOGPS
logP3.21ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)3.32ChemAxon
pKa (Strongest Basic)-0.64ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.76 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity82.68 m3·mol-1ChemAxon
Polarizability30.63 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Alpha-amino acid or derivatives
  • Benzenoid
  • 1,3-dicarbonyl compound
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Secondary carboxylic acid amide
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. [PubMed:8787774 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed:10668858 ]
  2. Sachs B, Erdmann S, Al-Masaoudi T, Merk HF: In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20. [PubMed:11251565 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23